Literature DB >> 7427242

Hydrallazine-induced lupus erythematosus-like syndrome in a patient of the rapid acetylator phenotype.

S J Harland, V Facchini, J A Timbrell.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 7427242      PMCID： PMC1713780          DOI： 10.1136/bmj.281.6235.273-a

Source DB:  PubMed          Journal:  Br Med J        ISSN： 0007-1447


× No keyword cloud information.
  4 in total

1.  HUMAN ACETYLATION POLYMORPHISM.

Authors:  D A EVANS; T A WHITE
Journal:  J Lab Clin Med       Date:  1964-03

Review 2.  Late toxicity to hydralazine resembling systemic lupus erythematosus or rheumatoid arthritis.

Authors:  H M Perry
Journal:  Am J Med       Date:  1973-01       Impact factor: 4.965

3.  Determination of hydralazine and its acetylated metabolites in urine by gas chromatography and high-pressure liquid chromatography.

Authors:  V Facchini; A J Streeter; J A Timbrell
Journal:  J Chromatogr       Date:  1980-01-04

4.  Acetylator phenotype in patients with hydralazine-induced lupoid syndrome.

Authors:  I Strandberg; G Boman; L Hassler; F Sjöqvist
Journal:  Acta Med Scand       Date:  1976
  4 in total
  10 in total

1.  Acrylamine-induced autoimmune phenomena.

Authors:  Bruce Rothschild
Journal:  Clin Rheumatol       Date:  2010-06-11       Impact factor: 2.980

2.  Hydralazine-induced peripheral neuropathy seen in a Japanese slow acetylator patient.

Authors:  G Tsujimoto; Y Horai; T Ishizaki; K Itoh
Journal:  Br J Clin Pharmacol       Date:  1981-06       Impact factor: 4.335

Review 3.  Clinical pharmacokinetics of hydralazine.

Authors:  T M Ludden; J L McNay; A M Shepherd; M S Lin
Journal:  Clin Pharmacokinet       Date:  1982 May-Jun       Impact factor: 6.447

4.  The lupus syndrome induced by hydralazine: a common complication with low dose treatment.

Authors:  H A Cameron; L E Ramsay
Journal:  Br Med J (Clin Res Ed)       Date:  1984-08-18

5.  Endralazine, a new peripheral vasodilator. Evaluation of safety and efficacy over a 3 year period.

Authors:  W A Bogers; L Meems
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 6.  Acetylator phenotype and lupus erythematosus.

Authors:  J P Uetrecht; R L Woosley
Journal:  Clin Pharmacokinet       Date:  1981 Mar-Apr       Impact factor: 6.447

Review 7.  Genetically determined variability in acetylation and oxidation. Therapeutic implications.

Authors:  D W Clark
Journal:  Drugs       Date:  1985-04       Impact factor: 9.546

8.  Hydralazine-induced lupus: is there a toxic metabolic pathway?

Authors:  J A Timbrell; V Facchini; S J Harland; R Mansilla-Tinoco
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

9.  Orogenital ulcers, SLE and hydralazine.

Authors:  E Neville; P Y Graham; R A Brewis
Journal:  Postgrad Med J       Date:  1981-06       Impact factor: 2.401

10.  Clinical Characteristics of Hydralazine-induced Lupus.

Authors:  Homa Timlin; Michael Wu; Monica Crespo-Bosque; Duvuru Geetha; Ashley Ingolia; Uzma Haque; Marilyn C Towns; Thomas Grader-Beck
Journal:  Cureus       Date:  2019-06-25
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.